| Autor: |
Fatih Gürler, Fatih Tay, Zehra Sucuoğlu İşleyen, Tahir Yerlikaya, Engin Hendem, Selin Aktürk Esen, Osman Sütçüoğlu, Deniz Işık, Büşra Niğdelioğlu, Miraç Özen, Elif Şahin, Teoman Şakalar, Nilay Şengül Samancı, Özkan Alan, İlhan Hacıbekiroğlu, Efnan Algın, Melek Karakurt Yılmaz, Hacı Mehmet Türk, Berna Öksüzoğlu, Aydın Yavuz, Osman Yüksel, Hüseyin Bora, Ozan Yazıcı, Ahmet Özet, Nuriye Özdemir |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Cancer Medicine, Vol 13, Iss 14, Pp n/a-n/a (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2045-7634 |
| DOI: |
10.1002/cam4.70002 |
| Popis: |
Abstract Background Neoadjuvant treatment is the standard treatment in locally advanced ESCC. However, the optimal chemotherapy regimen is not known. Method This is a retrospective observational cohort study conducted with propensity score matching. Patients with resectable ESCC from 13 tertiary centers from Türkiye were screened between January 2011 and December 2021. We compared the efficacy and safety of neoadjuvant chemoradiotherapy with the CF and the CROSS regimens in patients with ESCC. Results Three hundred and sixty‐two patients were screened. Patients who received induction chemotherapy (n = 72) and CROSS‐ineligible (n = 31) were excluded. Two hundred and fifty nine patients received neoadjuvant chemoradiotherapy. After propensity score matching (n = 97 in both groups), the mPFS was 18.4 months (95% CI, 9.3–27.4) and 25.7 months (95% CI, 15.6–35.7; p = 0.974), and the mOS was 35.2 months (95% CI, 18.9–51.5) and 39.6 months (95% CI 20.1–59.2; p = 0.534), in the CF and the CROSS groups, respectively. There was no difference between subgroups regarding PFS and OS. Compared with the CF group, the CROSS group had a higher incidence of neutropenia (34.0% vs. 62.9%, p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
